Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice

Neurobiology of Aging

Volumn 28, Issue 2, 2007, Pages 213-225

  Quinn, Joseph F ^a,b   Bussiere, Joseph R ^b   Hammond, Rebecca S ^b   Montine, Thomas J ^c   Henson, Edward ^d   Jones, Richard E ^a,b   Stackman Jr , Robert W ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid; Antioxidant; Context memory; Hippocampus; Nitrotyrosine; Spatial memory

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; ISOPROSTANE DERIVATIVE; NEUROPROSTANE; PROSTANOID; THIOCTIC ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE MODEL; FEMALE; HIPPOCAMPUS; LEARNING; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; TASK PERFORMANCE; TRANSGENIC MOUSE;

EID: 33845442944     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.12.014     Document Type: Article

References (91)

1. Abrisqueta-Gomez J., Bueno O.F., Oliveira M.G., and Bertolucci P.H. Recognition memory for emotional pictures in Alzheimer's patients. Acta Neurol Scand 105 1 (2002) 51-54
2. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., and Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 92 2 (2005) 255-263
3. Aksenov M., Aksenova M., Butterfield D.A., and Markesbery W.R. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74 6 (2000) 2520-2527
4. Arendash G.W., Gordon M.N., Diamond D.M., Austin L.A., Hatcher J.M., Jantzen P., et al. Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory. DNA Cell Biol 20 11 (2001) 737-744
5. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., et al. Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278 44 (2003) 42959-42965
6. Bastianetto S., Ramassamy C., Dore S., Christen Y., Poirier J., and Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur J Neurosci 12 6 (2000) 1882-1890
7. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77 6 (1994) 817-827
8. Boller F., El Massioui F., Devouche E., Traykov L., Pomati S., and Starkstein S.E. Processing emotional information in Alzheimer's disease: effects on memory performance and neurophysiological correlates. Dement Geriatr Cogn Disord 14 2 (2002) 104-112
9. Bruce A.J., Malfroy B., and Baudry M. β-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci 93 6 (1996) 2312-2316
10. Cahill L., and McGaugh J.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci 21 7 (1998) 294-299
11. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 5 (2004) 633-645
12. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2 3 (1999) 271-276
13. Chen H.J., Chen Y.M., and Chang C.M. Lipoyl dehydrogenase catalyzes reduction of nitrated DNA and protein adducts using dihydrolipoic acid or ubiquinol as the cofactor. Chem Biol Interact 140 3 (2002) 199-213
14. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276 24 (2001) 21562-21570
15. Corcoran K.A., Lu Y., Turner R.S., and Maren S. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Memory 9 5 (2002) 243-252
16. Cotman C.W., Head E., Muggenburg B.A., Zicker S., and Milgram N.W. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 23 5 (2002) 809-818
17. Dong H., Goico B., Martin M., Csernansky C.A., Bertchume A., and Csernansky J.G. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127 3 (2004) 601-609
18. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84 5 (2003) 1173-1183
19. Folch J., Ascoli I., Lees M., Meath J.A., and Le B.N. Preparation of lipid extracts from brain tissue. J Biol Chem 191 2 (1951) 833-841
20. Gabbita S.P., Lovell M.A., and Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71 5 (1998) 2034-2040
21. Gallagher M., Burwell R., and Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107 4 (1993) 618-626
22. Hagen T.M., Ingersoll R.T., Lykkesfeldt J., Liu J., Wehr C.M., Vinarsky V., et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. Faseb J 13 2 (1999) 411-418
23. Hagen T.M., Liu J., Lykkesfeldt J., Wehr C.M., Ingersoll R.T., Vinarsky V., et al. Feeding acetyl-l-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci 99 4 (2002) 1870-1875
24. Hager K., Marahrens A., Kenklies M., Riederer P., and Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32 3 (2001) 275-282
25. Hamann S., Monarch E.S., and Goldstein F.C. Impaired fear conditioning in Alzheimer's disease. Neuropsychology 40 8 (2002) 1187-1195
26. Harris M.E., Carney J.M., Cole P.S., Hensley K., Howard B.J., Martin L., et al. β-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Neuroreport 6 14 (1995) 1875-1879
27. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci 96 6 (1999) 3228-3233
28. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274 5284 (1996) 99-102
29. Huerta P.T., Sun L.D., Wilson M.A., and Tonegawa S. Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons. Neuron 25 2 (2000) 473-480
30. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., and Hyman B.T. APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56 9 (1997) 965-973
31. Janus C., and Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav 73 5 (2001) 873-886
32. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci 94 4 (1997) 1550-1555
33. Ju T.C., Chen S.D., Liu C.C., and Yang D.I. Protective effects of S-nitrosoglutathione against amyloid β-peptide neurotoxicity. Free Radical Biol Med 38 7 (2005) 938-949
34. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24 15 (2004) 3801-3809
35. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21 2 (2001) 372-381
36. Kayali R., Cakatay U., Akcay T., and Altug T. Effect of alpha-lipoic acid supplementation on markers of protein oxidation in post-mitotic tissues of ageing rat. Cell Biochem Funct (2004)
37. Kazui H., Mori E., Hashimoto M., Hirono N., Imamura T., Tanimukai S., et al. Impact of emotion on memory. Controlled study of the influence of emotionally charged material on declarative memory in Alzheimer's disease. Br J Psychiat 177 (2000) 343-347
38. Kim J.J., and Fanselow M.S. Modality-specific retrograde amnesia of fear. Science 256 5057 (1992) 675-677
39. King D.L., and Arendash G.W. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res 926 1-2 (2002) 58-68
40. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., and Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 103 2 (1999) 145-162
41. Koistinaho M., Ort M., Cimadevilla J.M., Vondrous R., Cordell B., Koistinaho J., et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc Natl Acad Sci 98 25 (2001) 14675-14680
42. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22 15 (2002) 6331-6335
43. Larson J., Lynch G., Games D., and Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840 1-2 (1999) 23-35
44. Liu J., Head E., Gharib A.M., Yuan W., Ingersoll R.T., Hagen T.M., et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-l-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci 99 4 (2002) 2356-2361
45. Liu L., Tapiola T., Herukka S.K., Heikkila M., and Tanila H. Aβ levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport 14 1 (2003) 163-166
46. Lovell M.A., Xie C., Xiong S., and Markesbery W.R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 5 3 (2003) 229-239
47. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 3 (1999) 853-862
48. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci 99 19 (2002) 12197-12202
49. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol 9 1 (1999) 133-146
50. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85 5 (2003) 1101-1108
51. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 6 (1999) 860-866
52. Moayeri S.E., Cahill L., Jin Y., and Potkin S.G. Relative sparing of emotionally influenced memory in Alzheimer's disease. Neuroreport 11 4 (2000) 653-655
53. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274 10 (1999) 6483-6492
54. Montine T.J., Neely M.D., Quinn J.F., Beal M.F., Markesbery W.R., Roberts L.J., et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biol Med 33 5 (2002) 620-626
55. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. Aß peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 6815 (2000) 982-985
56. Morris R.G.M., Garrud P., Rawlins J.N.P., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1982) 681-683
57. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts II L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci 87 23 (1990) 9383-9387
58. Morrow J.D., and Roberts II L.J. Mass spectrometry of prostanoids: F2 isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 233 (1994) 163-174
59. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20 11 (2000) 4050-4058
60. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6 1 (1995) 21-31
61. Nakagawa H., Sumiki E., Ikota N., Matsushima Y., and Ozawa T. Endogenous and new synthetic antioxidants for peroxynitrite: selective inhibitory effect of 5-methoxytryptamine and lipoic acid on tyrosine nitration by peroxynitrite. Antioxid Redox Signal 1 2 (1999) 239-244
62. Nakagawa H., Sumiki E., Takusagawa M., Ikota N., Matsushima Y., and Ozawa T. Scavengers for peroxynitrite: inhibition of tyrosine nitration and oxidation with tryptamine derivatives, alpha-lipoic acid and synthetic compounds. Chem Pharm Bull (Tokyo) 48 2 (2000) 261-265
63. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 8 (2001) 759-767
64. Packer L., Tritschler H.J., and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radical Biol Med 22 1-2 (1997) 359-378
65. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., et al. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152 4 (1998) 871-877
66. Phillips R.G., and LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106 2 (1992) 274-285
67. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 12 (2001) 4183-4187
68. Quinn J., Davis F., Woodward W.R., and Eckenstein F. β-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease. Exp Neurol 168 2 (2001) 203-212
69. Quinn J., Kulhanek D., Nowlin J., Jones R., Pratico D., Rokach J., et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 1037 1-2 (2005) 209-213
70. Quinn J., Montine T., Morrow J., Woodward W.R., Kulhanek D., and Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 137 1-2 (2003) 32-41
71. Rezk B.M., Haenen G.R., van der Vijgh W.J., and Bast A. Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage. J Biol Chem 279 11 (2004) 9693-9697
72. Roberts III L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273 22 (1998) 13605-13612
73. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 17 (1997) 1216-1222
74. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 5594 (2002) 789-791
75. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci 88 23 (1991) 10540-10543
76. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., et al. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70 5 (1998) 2212-2215
77. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17 8 (1997) 2653-2657
78. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., and Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184 1 (2003) 510-520
79. Stoll S., Hartmann H., Cohen S.A., and Muller W.E. The potent free radical scavenger alpha-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. Pharmacol Biochem Behav 46 4 (1993) 799-805
80. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 4 (1991) 572-580
81. Teunissen C.E., de Vente J., Steinbusch H.W., and De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23 4 (2002) 485-508
82. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., and Isobe C. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 269 1 (1999) 52-54
83. Tully A.M., Roche H.M., Doyle R., Fallon C., Bruce I., Lawlor B., et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89 4 (2003) 483-489
84. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., and De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17 2 (2003) 388-396
85. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 6880 (2002) 535-539
86. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 1 (2004) 181-193
87. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., Agnaf O.E., et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J Neurosci 25 10 (2005) 2455-2462
88. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 5 (2002) 1858-1867
89. 1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11 1 (1999) 83-90
90. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 7 (2005) 5892-5901
91. Yatin S.M., Aksenov M., and Butterfield D.A. The antioxidant vitamin E modulates amyloid β-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 24 3 (1999) 427-435